ImmuneOncia Therapeutics

At a glance

ImmuneOncia Therapeutics filed 45 disclosures in the last 12 months, including 6 insider, 2 5% holder and 1 issuance. The most recent key filing was on Jul 28.

Revenue for 2025 was ₩111.2M, down 83% on 2024. It made an operating loss of ₩28B. Debt was 17% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩0 and operating loss of ₩10B.

The 2025 annual report lists 22 employees with an average tenure of 2.7 years and average pay of ₩103.5M. Its 5 directors and auditors were paid ₩154M each on average. It paid no cash dividend for 2025. (주)유한양행 and related parties held 65.93% at year end.

From the 2025 annual report

Staff: 22 (7 men, 15 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩2.5B. Directors and auditors: 5, paid ₩769M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)유한양행 holds 65.93%; with 0 related parties the group holds 65.93% of common shares at year end (from 67.22% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary